Emmett Hannah E, Hall Jennifer, Webster Harriet H, Izzard Abigail, Singanayagam Anika, Zambon Maria, Dabrera Gavin
UK Field Epidemiology Training Programme, UK Health Security Agency, London, UK.
COVID-19 Vaccines and Epidemiology Division, UK Health Security Agency, London, UK.
Influenza Other Respir Viruses. 2025 Jun;19(6):e70116. doi: 10.1111/irv.70116.
Early in the COVID-19 pandemic, due to limited testing, a potential gap in capturing SARS-CoV-2-positive community deaths was identified. Post-mortem testing for respiratory viruses had never been implemented in the United Kingdom.
Through implementing and evaluating a pilot, we aimed to establish feasibility and acceptability of post-mortem SARS-CoV-2 surveillance using funeral directors (FDs) to capture 'missed' COVID-19 community deaths.
Between January 2021 and February 2022, four FDs took upper respiratory tract samples from eligible people who died outside hospital. We tested for SARS-CoV-2 and other respiratory viruses using reverse transcription-polymerase chain reaction and matched results to the national COVID-19 mortality dataset. We evaluated the pilot for acceptability, data completeness and timeliness, and simplicity, using semi-structured interviews, a questionnaire, and data audit.
Two thousand eight hundred sixty-five deaths were handled by FDs: 998 were assessed for eligibility, 342 were eligible 81 were tested. Eight were SARS-CoV-2-positive, of which three were not identified by ante-mortem clinical testing. The programme was acceptable in principle to FDs and families, but FDs' participation was limited by the burden of legal requirements and existing workloads. Families' willingness to consent fluctuated (monthly consent rate 4-83%, overall 30%); fewer consented when overall cases were low. Completeness and timeliness of data was good. FDs judged the programme simple.
The pilot established feasibility and demonstrated, even with small numbers, the ability to detect 'missed' deaths. There were significant obstacles to implementation. Alternative settings for taking specimens are being explored instead to address this gap in national surveillance.
在新冠疫情早期,由于检测能力有限,发现了在记录严重急性呼吸综合征冠状病毒2(SARS-CoV-2)阳性社区死亡病例方面可能存在的缺口。英国从未开展过针对呼吸道病毒的尸检检测。
通过实施和评估一项试点项目,我们旨在确定利用丧葬承办人(FDs)进行SARS-CoV-2尸检监测以记录“漏报”的新冠社区死亡病例的可行性和可接受性。
在2021年1月至2022年2月期间,四名丧葬承办人从在医院外死亡的符合条件的人员身上采集上呼吸道样本。我们使用逆转录-聚合酶链反应检测SARS-CoV-2和其他呼吸道病毒,并将结果与国家新冠死亡数据集进行匹配。我们通过半结构化访谈、问卷调查和数据审核,对该试点项目的可接受性、数据完整性和及时性以及简易性进行了评估。
丧葬承办人处理了2865例死亡病例:998例接受了资格评估,342例符合条件,81例接受了检测。8例为SARS-CoV-2阳性,其中3例生前临床检测未发现。该项目原则上为丧葬承办人和家属所接受,但丧葬承办人的参与受到法律要求负担和现有工作量的限制。家属的同意意愿波动较大(每月同意率4%-83%,总体为30%);总体病例数较低时,同意的家属较少。数据的完整性和及时性良好。丧葬承办人认为该项目简单。
该试点项目确定了可行性,并且即使数量较少,也证明了有能力检测出“漏报”的死亡病例。实施过程中存在重大障碍。正在探索替代的样本采集场所,以弥补国家监测中的这一缺口。